DelveInsight releases Glioblastoma Pipeline Insight 2023 offering insights into glioblastoma pipeline featuring 195 companies and 210 pipeline drugs; assessment includes product type, development stage, route of administration and molecule type

Sample article from our Health Care Sector

December 5, 2023 (press release) –

DelveInsight's, "Glioblastoma Pipeline Insight 2023" report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in the Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Glioblastoma Pipeline Report

  • DelveInsight's Glioblastoma pipeline report depicts a robust space with 195+ active players working to develop 210+ pipeline therapies for Glioblastoma treatment.
  • The leading companies working in the Glioblastoma Market include Denovo BioPharma, Pfizer , Vigeo Therapeutics, Celldex Therapeutics , Debiopharm , Prelude Therapeutics , AiVita Biomedical, Ascletis Pharma , Kintara Therapeutics , Bayer AG , Kazia Therapeutics , GlaxoSmithKline , Candel Therapeutics , Symphogen A/S , Sanofi , Oblato, Jiangsu Hengrui Medicine , BPGbio, Inc. , Alaunos Therapeutics , Eli Lilly and Company , Actuate Therapeutics, Oncotelic Therapeutics , The Menarini Group , SonALAsense, Novartis , Allarity Therapeutics , PharmAbcine , I-Mab Biopharma Co. Ltd. , Aadi Bioscience Inc. , Matrix Biomed, Photonamic GmbH & Co. KG , Lixte, Black Diamond Therapeutics , Tmunity Therapeutics , SOM Biotech, Moleculin, Xynomic Pharmaceuticals , OncoSynergy , and others.
  • Promising Glioblastoma Pipeline Therapies in the various stages of development include Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, LAM561, Onfekafusp Alfa, and others.
  • November 2023 : Boston Scientific Corporation announced a study of early Phase 1 clinical trials for TheraSphere GBM. The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
  • November 2023 : Chimeric Therapeutics announced a study of Phase 1 clinical trials for CHM-1101 CAR-T cells. This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the effectiveness of CHM-1101 in treating MMP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive).
  • November 2023 : In8Bio Inc. announced a study of Phase 1 & 2 clinical trials for Autologous genetically modified gamma-delta T cells. A Phase 1b / 2 Open-label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide (TMZ) in Subjects With Recurrent or Newly Diagnosed Glioblastoma.
  • November 2023 : Novartis Pharmaceuticals announced a study of Phase 1 clinical trials for Temozolomide and Radiotherapy. A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Radiotherapy With or Without Temozolomide and in Recurrent Glioblastoma as Single Agent.

 

Request a sample and discover the recent advances in Glioblastoma Treatment Drugs @ Glioblastoma Pipeline Outlook Report

 

In the Glioblastoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Glioblastoma Overview

Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. Somatic evolution promotes the progression of cancer in which the genome of the cancer cell is being deviated from that of the healthy cell due the accumulation of mutations.

 

Find out more about Glioblastoma Treatment Landscape @ Drugs for Glioblastoma Treatment

 

Glioblastoma Emerging Drugs Profile

  • Enzastaurin: Denovo BioPharma
  • Tofacitinib: Pfizer
  • VT1021: Vigeo Therapeutics
  • Varlilumab: Celldex Therapeutics
  • Debio 0123: Debiopharm
  • PRT3645: Prelude Therapeutics

 

Glioblastoma Pipeline Therapeutics Assessment

There are approx. 195+ key companies which are developing the therapies for Glioblastoma. The Glioblastoma companies which have their Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Denovo BioPharma.

 

DelveInsight's Glioblastoma pipeline report covers around 210+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Glioblastoma Pipeline Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Learn more about the emerging Glioblastoma Pipeline Therapies @ Glioblastoma Clinical Trials Assessment

 

Scope of the Glioblastoma Pipeline Report

  • Coverage- Global
  • Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Glioblastoma Companies- Denovo BioPharma, Pfizer , Vigeo Therapeutics, Celldex Therapeutics , Debiopharm , Prelude Therapeutics , AiVita Biomedical, Ascletis Pharma , Kintara Therapeutics , Bayer AG , Kazia Therapeutics , GlaxoSmithKline , Candel Therapeutics , Symphogen A/S , Sanofi , Oblato, Jiangsu Hengrui Medicine , BPGbio, Inc. , Alaunos Therapeutics , Eli Lilly and Company , Actuate Therapeutics, Oncotelic Therapeutics , The Menarini Group , SonALAsense, Novartis , Allarity Therapeutics , PharmAbcine , I-Mab Biopharma Co. Ltd. , Aadi Bioscience Inc. , Matrix Biomed, Photonamic GmbH & Co. KG , Lixte, Black Diamond Therapeutics , Tmunity Therapeutics , SOM Biotech, Moleculin, Xynomic Pharmaceuticals , OncoSynergy , and others.
  • Glioblastoma Pipeline Therapies- Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, LAM561, Onfekafusp Alfa, and others.

 

Dive deep into rich insights for new drugs for Glioblastoma treatment, Visit @ Glioblastoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Glioblastoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Glioblastoma- DelveInsight's Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Enzastaurin: Denovo BioPharma
  9. Drug profiles in the detailed report.....
  10. Mid Stage Products (Phase II)
  11. Varlilumab: Celldex Therapeutics
  12. Drug profiles in the detailed report.....
  13. Early Stage Products (Phase I)
  14. PRT3645: Prelude Therapeutics
  15. Drug profiles in the detailed report.....
  16. Preclinical and Discovery Stage Products
  17. ELC-401: Elicera Therapeutics
  18. Drug profiles in the detailed report.....
  19. Inactive Products
  20. Glioblastoma Key Companies
  21. Glioblastoma Key Products
  22. Glioblastoma- Unmet Needs
  23. Glioblastoma- Market Drivers and Barriers
  24. Glioblastoma- Future Perspectives and Conclusion
  25. Glioblastoma Analyst Views
  26. Glioblastoma Key Companies
  27. Appendix

 

For further information on the Glioblastoma pipeline therapeutics, reach out @ Glioblastoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name : DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/supraventricular-tachycardia-market

 

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Glioblastoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Denovo BioPharma, Pfizer , Vigeo Therapeutics, Celldex Therapeutics , Debiopharm , Prelude Therapeutics , and others.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.